| Download the amazing global Makindo app: ✅ Means NICE/National Guidelines 2026 compliant Android | Apple | |
|---|---|
| MEDICAL DISCLAIMER: Educational use only. Not for diagnosis or management. See below for full disclaimer. |
Clinical summary: This entry requires a disease-specific recognition, red-flag and emergency-management review. Refer to the underlying article and current local pathway; do not use this panel as a treatment protocol.
Browse the Neurology & Stroke textbook: Neurology: Emergencies (specialty landing page only; no disease-level match confirmed)
References: Existing source link (not yet checked)
Editorial draft: the full historic text, doses, and pathways have not been clinically signed off. Cross-check BNF/BNFC and local protocols.
Anticoagulation and reversal are high-risk prescribing decisions. The historic article retains abbreviated dose examples not individually checked against every indication or product; they must not be used as prescriptions. Follow current BNF/SmPC, local anticoagulation pathways and specialist advice. Sources: NICE NG158 and NHS SPS.
⚠️ Safety Alert: Always monitor for a platelet fall (>50% or to <150) between days 5–14 of heparin exposure → may signal Heparin-Induced Thrombocytopenia (HIT), which is pro-thrombotic, not bleeding-related. ➡️ Stop all heparin immediately and seek urgent haematology advice.
⚠️ Unfractionated heparin infusions: there is no transferable aPTT-to-infusion adjustment table. Use the current trust-specific, indication-specific weight-based UFH protocol, including baseline tests, locally calibrated aPTT or anti-Xa targets, repeat sampling, contraindications and a clear escalation pathway. Never use an illustrative table to prescribe an IV infusion.
⚠️ Do not prescribe from the abbreviated dose examples below. AF and acute VTE have different dosing phases and dose-reduction rules. Calculate creatinine clearance using Cockcroft–Gault (not eGFR alone), verify weight, age, renal/liver function, indication, interactions and the drug-specific current SmPC/BNF. Arrange baseline and ongoing FBC, renal and liver monitoring; review more often in frailty, intercurrent illness or renal impairment. Source: NHS SPS DOAC monitoring (updated October 2026).
🧠 Makindo clinical pearl: Always ask WHY the patient is anticoagulated, HOW LONG for, and WHEN it should be reviewed. Anticoagulants can cause or worsen bleeding; also investigate underlying lesions and competing explanations for clinical deterioration.
| Drug | Reversal Agent | Dose / Notes |
|---|---|---|
| Warfarin | Vitamin K + PCC |
• Vitamin K 5–10 mg IV (slow)
• PCC (Beriplex/Octaplex) per INR & weight • If PCC is unavailable, urgently consult haematology and the local major-haemorrhage protocol; FFP is not a routine equivalent substitute |
| UFH | Protamine sulfate |
• 1 mg protamine per 100 IU heparin (max 50 mg)
• Give IV slowly (hypotension/anaphylaxis risk) |
| LMWH | Protamine (partial) |
• Partial reversal only
• 1 mg per 1 mg enoxaparin if within 8 h |
| Dabigatran | Idarucizumab |
• 5 g IV (2 × 2.5 g)
• Immediate and complete reversal |
| Apixaban / Rivaroxaban | Andexanet alfa* |
• Specialist use only
• PCC often used if unavailable |
⚠️ Makindo safety tip: Reversal decisions depend on bleeding severity, drug timing, and thrombotic risk. Always involve haematology in major bleeding.
| Feature | UFH | LMWH | DOACs | Warfarin |
|---|---|---|---|---|
| Onset | Immediate | Hours | Rapid | Slow (days) |
| Monitoring | aPTT | Platelets, renal function; anti-Xa in selected cases | None | INR |
| Renal failure | ✔ Safe | ⚠ Dose adjust | ⚠ Often avoid | ✔ Safe |
| Reversal | ✔ Protamine | ⚠ Partial | ✔ (agent-specific) | ✔ Vit K / PCC |
| Pregnancy | ✔ | ✔ First-line | ✖ Avoid | ✖ Teratogenic |
🧠 Makindo final pearl: If a patient on anticoagulation deteriorates, always ask: Is this bleeding? Is this HIT? Or is this the disease progressing? Pattern recognition + physiology beats rote dosing every time.